21 studies found for:    Lupus AND Los Angeles | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
Lupus AND Los Angeles | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Abatacept for SLE Arthritis (IM101-330)
Condition: Systemic Lupus Erythematosus Arthritis
Interventions: Drug: abatacept;   Drug: Placebo
2 Recruiting Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
Condition: Systemic Lupus Erythematosus
Interventions: Biological: BENLYSTA;   Other: SLE treatment
3 Recruiting A Complex Contraception Registry
Conditions: Diabetes;   Cardiovascular Disease;   Epilepsy;   Migraine;   Neurological Disorders;   Cancer;   Bariatric Surgery Candidate;   Organ or Tissue Transplant; Complications;   Lupus Erythematosus, Systemic;   Other Hematologic Conditions;   Other Venous Embolism and Thrombosis
Intervention:
4 Recruiting Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
5 Recruiting Nelfinavir in Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Nelfinavir
6 Recruiting A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
Condition: Systemic Lupus Erythematosus
Interventions: Drug: CC-220;   Drug: Placebo
7 Recruiting Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
Conditions: Systemic Lupus Erythematosus;   SLE
Interventions: Drug: Mycophenolate Mofetil;   Drug: Hydroxychloroquine or Chloroquine;   Drug: Prednisone
8 Recruiting A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Baricitinib;   Drug: Placebo
9 Recruiting Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
10 Recruiting Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Anifrolumab;   Drug: Placebo
11 Recruiting MSC2364447C Phase 1b in Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: MSC2364447C;   Drug: Placebo
12 Recruiting A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: IPP-201101;   Drug: Placebo;   Other: Standard of Care
13 Recruiting Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients.
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Belimumab
14 Recruiting Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Condition: Active Systemic Lupus Erythematosus
Interventions: Biological: Anifrolumab;   Drug: Placebo
15 Recruiting Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: BI 655064 dose 1;   Drug: BI 655064 dose 2;   Drug: BI 655064 dose 3;   Drug: Placebo
16 Recruiting A Study to Evaluate the Safety and Efficacy of Obinutuzumab, an Antibody Targeting Certain Types of Immune Cells, in Participants With Lupus Nephritis (LN)
Condition: Lupus Nephritis
Interventions: Drug: Mycophenolate Mofetil;   Drug: Obinutuzumab;   Drug: Placebo
17 Recruiting Belimumab Assessment of Safety in SLE
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Other: Standard therapy
18 Recruiting Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Condition: Active Systemic Lupus Erythematosus
Interventions: Biological: Anifrolumab;   Drug: Placebo
19 Not yet recruiting MsciSLE: MSCs in SLE Trial
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Low Dose Mesenchymal Stem Cells (MSCs);   Drug: High Dose Mesenchymal Stem Cells (MSCs);   Drug: Placebo Infusion
20 Recruiting Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Interventions: Drug: tofacitinib;   Biological: adalimumab;   Biological: etanercept

   Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results    Last Page
Indicates status has not been verified in more than two years